Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

68 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Fibroblast growth factors and their receptors in urological cancers: basic research and clinical implications.
Cronauer MV, Schulz WA, Seifert HH, Ackermann R, Burchardt M. Cronauer MV, et al. Eur Urol. 2003 Mar;43(3):309-19. doi: 10.1016/s0302-2838(03)00005-8. Eur Urol. 2003. PMID: 12600436 Review.
Re: Christoph A. Von Klot, Markus A. Kuczyk, Axel S. Merseburger. No androgen withdrawal syndrome for enzalutamide: a report of disease dynamics in the postchemotherapy setting. Eur Urol 2014;65:258-9: Enzalutamide withdrawal syndrome: fact or fiction?
Schrader AJ, Schrader MG, Cronauer MV. Schrader AJ, et al. Among authors: cronauer mv. Eur Urol. 2014 Feb;65(2):e22-3. doi: 10.1016/j.eururo.2013.10.034. Epub 2013 Nov 1. Eur Urol. 2014. PMID: 24210913 No abstract available.
Stilbene induced inhibition of androgen receptor dimerization: implications for AR and ARΔLBD-signalling in human prostate cancer cells.
Streicher W, Luedeke M, Azoitei A, Zengerling F, Herweg A, Genze F, Schrader MG, Schrader AJ, Cronauer MV. Streicher W, et al. Among authors: cronauer mv. PLoS One. 2014 Jun 2;9(6):e98566. doi: 10.1371/journal.pone.0098566. eCollection 2014. PLoS One. 2014. PMID: 24887556 Free PMC article.
Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone.
Schrader AJ, Boegemann M, Ohlmann CH, Schnoeller TJ, Krabbe LM, Hajili T, Jentzmik F, Stoeckle M, Schrader M, Herrmann E, Cronauer MV. Schrader AJ, et al. Among authors: cronauer mv. Eur Urol. 2014 Jan;65(1):30-6. doi: 10.1016/j.eururo.2013.06.042. Epub 2013 Jul 2. Eur Urol. 2014. PMID: 23849416
Inhibition of IGF-1R diminishes transcriptional activity of the androgen receptor and its constitutively active, C-terminally truncated counterparts Q640X and AR-V7.
Zengerling F, Azoitei A, Herweg A, Jentzmik F, Cronauer MV. Zengerling F, et al. Among authors: cronauer mv. World J Urol. 2016 May;34(5):633-9. doi: 10.1007/s00345-015-1674-5. Epub 2015 Aug 29. World J Urol. 2016. PMID: 26318637
Androgen receptor aberrations in the era of abiraterone and enzalutamide.
Jentzmik F, Azoitei A, Zengerling F, Damjanoski I, Cronauer MV. Jentzmik F, et al. Among authors: cronauer mv. World J Urol. 2016 Mar;34(3):297-303. doi: 10.1007/s00345-015-1624-2. Epub 2015 Jun 23. World J Urol. 2016. PMID: 26100946 Review.
Corpulence is the crucial factor: association of testosterone and/or obesity with prostate cancer stage.
Jentzmik F, Schnoeller TJ, Cronauer MV, Steinestel J, Steffens S, Zengerling F, Al Ghazal A, Schrader MG, Steinestel K, Schrader AJ. Jentzmik F, et al. Among authors: cronauer mv. Int J Urol. 2014 Oct;21(10):980-6. doi: 10.1111/iju.12494. Epub 2014 May 27. Int J Urol. 2014. PMID: 24865433
Re: J. Alfred Witjes. A case of abiraterone acetate withdrawal. Eur urol 2013;64:517-8.
Cronauer MV, Schrader MG, Schrader AJ. Cronauer MV, et al. Eur Urol. 2014 Jan;65(1):e10-1. doi: 10.1016/j.eururo.2013.08.035. Epub 2013 Aug 26. Eur Urol. 2014. PMID: 23993161 No abstract available.
NF-κB signaling in prostate cancer: a promising therapeutic target?
Jain G, Cronauer MV, Schrader M, Möller P, Marienfeld RB. Jain G, et al. Among authors: cronauer mv. World J Urol. 2012 Jun;30(3):303-10. doi: 10.1007/s00345-011-0792-y. Epub 2011 Nov 16. World J Urol. 2012. PMID: 22085980 Review.
Inhibition of p53 function diminishes androgen receptor-mediated signaling in prostate cancer cell lines.
Cronauer MV, Schulz WA, Burchardt T, Ackermann R, Burchardt M. Cronauer MV, et al. Oncogene. 2004 Apr 29;23(20):3541-9. doi: 10.1038/sj.onc.1207346. Oncogene. 2004. PMID: 15077179
68 results
Jump to page